Memory loss is one of the most common and anxiety-provoking complaints in medicine. Over the past five years, the evaluation of cognitive decline has become remarkably refined. No longer is memory loss assessed solely to “rule out dementia.” Today, clinicians have tools to detect the beginnings of Alzheimer’s disease or other neurodegenerative conditions before major symptoms appear, allowing patients to make informed decisions about their work, life, and health.
The first step remains the comprehensive history. Talking with both the patient and a close informant, often a spouse, helps identify subtle changes in memory, attention, or daily functioning. This dialogue often reveals what the patient may not notice themselves, providing a clearer picture of cognitive decline. A focused neurological exam follows, including cognitive screening with tools such as the Mini-Mental State Exam (MMSE) and assessment for parkinsonism or other movement disorders. These findings help differentiate Alzheimer’s disease from Lewy body dementia, Parkinson’s disease dementia, and other conditions with overlapping features. Importantly, up to 40 percent of patients with Alzheimer’s disease may develop parkinsonism, which can influence diagnosis, prognosis, and management.
Mild cognitive impairment (MCI) is now recognized as a separate diagnosis, lying between normal aging and dementia. Patients with MCI have measurable cognitive changes (often in memory, attention, or executive function), but these changes do not yet interfere significantly with daily life. Prognosis is variable: roughly 50 percent of patients remain stable for years, while the other 50 percent may gradually progress to dementia, including Alzheimer’s disease. This variability makes ongoing monitoring essential. Regular follow-up allows clinicians to track changes, adjust interventions, and provide timely guidance about planning and care.
Next comes objective testing. High-resolution MRI of the brain is used to identify structural changes, such as hippocampal or temporal lobe atrophy, while EEG can rule out seizure activity and detect patterns consistent with encephalopathy. For patients who demonstrate even mild cognitive decline on their examination, amyloid PET imaging visualizes amyloid deposits in the brain, providing a hallmark of pathology years before significant memory loss occurs. While amyloid PET can detect the hallmark plaques of Alzheimer’s disease, it cannot confirm the diagnosis on its own; clinical evaluation remains essential to determine whether cognitive changes are truly due to Alzheimer’s pathology. Laboratory evaluation remains crucial to exclude reversible causes. This typically includes thyroid function tests (TSH, T4), vitamin B12, and markers of systemic inflammation (ESR, CRP). Advanced biomarkers, including plasma P-tau 217 and the amyloid-beta 42/40 ratio, are increasingly available and allow clinicians to detect early Alzheimer’s pathology with a simple blood test that is approximately 90 percent accurate. Unfortunately, only patients with Medicare can get an Amyloid PET scan, so the above laboratory testing is helpful for all patients, regardless of insurance.
Once the diagnosis is clarified, treatment is individualized. Oral medications such as donepezil or memantine remain first-line options to support cognition. In carefully selected patients, intravenous anti-amyloid therapies may be considered to slow disease progression. Patients being considered for intravenous anti-amyloid therapy often are referred to a tertiary cognitive or memory disorders center, where expertise and MRI monitoring are available to manage potential complications such as ARIA-H (hemorrhage) and ARIA-E (edema). Many patients also benefit from adjunctive medications, such as sertraline or other antidepressants, to address mood symptoms or anxiety, which are common in early cognitive decline. Low-dose antipsychotic medications such as quetiapine are sometimes used to manage paranoia, delusions, or agitation in dementia, but must be used cautiously due to potential side effects. Lifestyle interventions, such as physical activity, cognitive engagement, social connection, and cardiovascular risk management, remain essential for maintaining overall function.
What sets this approach apart is the real-world implications of early detection. Knowing the beginnings of Alzheimer’s disease affects more than just medication decisions. Patients may need to plan work responsibilities, driving safety, finances, and estate considerations while their cognition is still relatively intact. Early knowledge empowers patients and families to make thoughtful, proactive choices rather than reactively responding to crises. As a neurologist, I find it deeply gratifying to guide patients through this process. Providing clear, personalized information about their condition allows them to make informed decisions about their work, life, and health, and to plan proactively while they still can. That sense of helping patients navigate not just their illness, but their future, is one of the most rewarding aspects of my practice.
In practice, evaluating memory loss today is about precision and personalization. Clinicians combine history, examination, imaging, EEG, laboratory tests, biomarkers, and individualized therapy (including IV anti-amyloid therapy and supportive medications like SSRIs) to create a comprehensive roadmap. This approach ensures that each patient receives care targeted to their biology, while also addressing life planning and functional outcomes. Memory loss may be an inevitable part of aging for some, but modern diagnostics allow us to catch disease early, act proactively, and preserve quality of life. By combining science with empathy, we give patients clarity and control at one of life’s most uncertain crossroads.
Scott Tzorfas is a neurologist.
